Cited by 99Malaria Research and ControlPharmaceutical Quality and CounterfeitingPhytochemical compounds biological activities

Efficacy and safety of artemether–lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial

Piola, Patrice, Nabasumba, Carolyn, Turyakira, Eleanor, Dhorda, Mehul, Lindegardh, Niklas, Nyehangane, Dan, Snounou, Georges, Ashley, Elizabeth A +3 more·2010·The Lancet Infectious Diseases

Abstract

Background Malaria in pregnancy is associated with maternal and fetal morbidity and mortality. In 2006, WHO recommended use of artemisinin-based combination treatments during the second or third trimesters, but data on efficacy and safety in Africa were scarce. We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda. Methods We did an open-label, randomised, non-inferiority trial between October, 2006, and May, 2009, at the antenatal clinics of the Mbarara University of Science and Technology Hospital in Uganda. Pregnant women were randomly assigned (1:1) by computer generated sequence to receive either quinine hydrochloride or artemether-lumefantrine, and were followed up weekly until delivery. Our primary endpoint was cure rate at day 42, confirmed by PCR. The non-inferiority margin was a difference in cure rate of 5%. Analysis of efficacy was for all randomised patients without study deviations that could have affected the efficacy outcome. This study was registered with ClinicalTrials.gov, number NCT00495508. Findings 304 women were randomly assigned, 152 to each treatment group. By day 42, 16 patients were lost to follow-up and 25 were excluded from the analysis. At day 42, 137 (99.3%) of 138 patients taking artemether-lumefantrine and 122 (97.6%) of 125 taking quinine were cured-difference 1.7% (lower limit o…

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(10)70202-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AL was safe and well tolerated.

    “AL was safe and well tolerated.136–138”

    From Malaria in pregnancy. (2013) · cites this paper as [136]

  • In Uganda, artemether-Lumefantrine (AL) was efficacious, with cure rates >95%.

    “In Uganda, in an area of relatively high transmission and hence with pregnant women having some acquired immunity, artemether-Lumefantrine (AL) was efficacious, with cure rates >95%.136–137”

    From Malaria in pregnancy. (2013) · cites this paper as [136]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Piola, P., Nabasumba, C., Turyakira, E., Dhorda, M., Lindegardh, N., Nyehangane, D., Snounou, G., Ashley, E. A., McGready, R., Nosten, F., & Guerin, P. J.
Affiliations
  • University of Oxford (GB)
  • Epicentre Uganda (UG)
  • Mbarara University of Science and Technology (UG)
  • Inserm (FR)
  • Epicentre (FR)
  • Mahidol University (TH)
Corresponding author
Piola, Patrice
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2010-11
Volume
10
Issue
11
Pages
762-769
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2132453006
Cited by
99
References
3
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 10 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 10 · 2014: 10 · 2013: 10 · 2012: 10
FWCI
9.80
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Medecins Sans Frontieres Field Research (Medecins Sans Frontieres) (submittedVersion)
Funders
  • Global Fund to Fight AIDS, Tuberculosis and Malaria
  • Wellcome Trust (077166/Z/05/Z)
  • University of Oxford
  • Mbarara University of Science and Technology
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phytochemical compounds biological activities
Keywords
artemether-lumefantrine, quinine, malaria in pregnancy, Plasmodium falciparum, uncomplicated malaria, artemisinin-based combination therapy, cure rate, drug safety, second and third trimester, malaria treatment
MeSH terms
Artemether, Lumefantrine Drug Combination, Adolescent, Adult, Animals, Antimalarials, Drug Combinations, Ethanolamines, Female, Fluorenes, Humans, Plasmodium falciparum, Pregnancy, Pregnancy Complications, Infectious, Quinine, Uganda, Polymerase Chain Reaction, Malaria, Falciparum, Treatment Outcome, Artemisinins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review